Get started
SANGAMO THERAPEUTICS INC COM USD0.01SANGAMO THERAPEUTICS INC COM USD0.01SANGAMO THERAPEUTICS INC COM USD0.01

SANGAMO THERAPEUTICS INC COM USD0.01

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

0R1D chart


Full chart

0R1D upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪585.10 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.3765 USD
Net income (FY)
‪−257.83 M‬ USD
Revenue (FY)
‪176.23 M‬ USD
Shares float
‪198.63 M‬
Beta (1Y)
−1.54

Employees


Employees (FY)
405
Change (1Y)
−73 −15.27%
Revenue / Employee (1Y)
‪435.14 K‬ USD
Net income / Employee (1Y)
‪−636.62 K‬ USD

About Sangamo Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Alexander D. Macrae
Website
sangamo.com
Headquarters
Richmond
Founded
1995
FIGI
BBG00JRY9H89
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

0R1D news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 0R1D is 3.0090 USD — it has increased by 9.62% in the past 24 hours. Watch SANGAMO THERAPEUTICS INC COM USD0.01 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange SANGAMO THERAPEUTICS INC COM USD0.01 stocks are traded under the ticker 0R1D.
0R1D stock has risen by 68.10% compared to the previous week, the month change is a 276.03% rise, over the last year SANGAMO THERAPEUTICS INC COM USD0.01 has showed a 668.78% increase.
We've gathered analysts' opinions on SANGAMO THERAPEUTICS INC COM USD0.01 future price: according to them, 0R1D price has a max estimate of 10.00 USD and a min estimate of 1.00 USD. Watch 0R1D chart and read a more detailed SANGAMO THERAPEUTICS INC COM USD0.01 stock forecast: see what analysts think of SANGAMO THERAPEUTICS INC COM USD0.01 and suggest that you do with its stocks.
0R1D reached its all-time high on Mar 12, 2018 with the price of 26.3500 USD, and its all-time low was 0.2900 USD and was reached on Nov 13, 2023. View more price dynamics on 0R1D chart.
See other stocks reaching their highest and lowest prices.
0R1D stock is 18.61% volatile and has beta coefficient of −1.54. Track SANGAMO THERAPEUTICS INC COM USD0.01 stock price on the chart and check out the list of the most volatile stocks — is SANGAMO THERAPEUTICS INC COM USD0.01 there?
Today SANGAMO THERAPEUTICS INC COM USD0.01 has the market capitalization of ‪597.59 M‬, it has increased by 33.56% over the last week.
Yes, you can track SANGAMO THERAPEUTICS INC COM USD0.01 financials in yearly and quarterly reports right on TradingView.
SANGAMO THERAPEUTICS INC COM USD0.01 is going to release the next earnings report on Nov 12, 2024. Keep track of upcoming events with our Earnings Calendar.
0R1D earnings for the last quarter are −0.18 USD per share, whereas the estimation was −0.15 USD resulting in a −22.68% surprise. The estimated earnings for the next quarter are −0.02 USD per share. See more details about SANGAMO THERAPEUTICS INC COM USD0.01 earnings.
SANGAMO THERAPEUTICS INC COM USD0.01 revenue for the last quarter amounts to ‪356.00 K‬ USD, despite the estimated figure of ‪6.88 M‬ USD. In the next quarter, revenue is expected to reach ‪20.92 M‬ USD.
0R1D net income for the last quarter is ‪−36.13 M‬ USD, while the quarter before that showed ‪−49.09 M‬ USD of net income which accounts for 26.40% change. Track more SANGAMO THERAPEUTICS INC COM USD0.01 financial stats to get the full picture.
No, 0R1D doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 10, 2024, the company has 405.00 employees. See our rating of the largest employees — is SANGAMO THERAPEUTICS INC COM USD0.01 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SANGAMO THERAPEUTICS INC COM USD0.01 EBITDA is ‪−186.69 M‬ USD, and current EBITDA margin is −52.26%. See more stats in SANGAMO THERAPEUTICS INC COM USD0.01 financial statements.
Like other stocks, 0R1D shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SANGAMO THERAPEUTICS INC COM USD0.01 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SANGAMO THERAPEUTICS INC COM USD0.01 technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SANGAMO THERAPEUTICS INC COM USD0.01 stock shows the buy signal. See more of SANGAMO THERAPEUTICS INC COM USD0.01 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.